OS Therapies Inc
OSTX evidence brief
What we can confirm
- BioSniper Score:
- 4.2 / 10
- Market Cap:
- $78.6M
- Lead Asset:
- ost-her2 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for OSTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OSTX
OS Therapies Inc (OSTX) is a clinical-stage biopharmaceutical company focused on developing gene-edited, Listeria-based immunotherapies for osteosarcoma and other solid tumors, with lead candidate OST-HER2 in Phase 2 for metastatic osteosarcoma.
Key risk: Negative equity and net loss
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$78.6M
Cash Runway
—
Lead Asset
ost-her2 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for OS Therapies Inc.
Similar companies
OS Therapies Inc (OSTX) is a clinical-stage biopharmaceutical company focused on developing gene-edited, Listeria-based immunotherapies for osteosarcoma and other solid tumors, with lead candidate OST-HER2 in Phase 2 for metastatic osteosarcoma.
- Lead candidate OST-HER2 is a genetically weakened Listeria monocytogenes strain expressing HER2 peptides, in Phase 2 for osteosarcoma with Orphan Drug status [pipeline].
- Net income of -$8.6M and shareholders' equity of -$11.9M as of 2026-06-30 [sec].
- Cash runway extended into 2027 via $5.5M financing (April 2026) and $5.7M raised in Q1-2026 [news · 2026-05-18].
- Interim 3-year overall survival data for OST-HER2 expected in early September 2026 [news · 2026-08-17].
- FDA Type C Statistical Methods Meeting scheduled for mid-September 2026 to review 2.5-year OS data and align on Phase 3 design for BLA under Accelerated Approval [news · 2026-08-17].
What works
- Multiple non-dilutive funding sources from UK subsidiary VAT refunds and R&D tax credits, including $1.9M VAT cash refund expected June 2026 [news · 2026-05-18].
- Successful EMA and Australia TGA meetings aligned on biomarker use and pending 3-year OS data to support Conditional Marketing [news · 2026-05-18].
- Up to $10M debt financing supported by UK subsidiary refunds, with $5M funded at first closing August 10, 2026 [news · 2026-08-17].
What to weigh
- Negative shareholders' equity of -$11.9M as of 2026-06-30 indicates accumulated deficit exceeding assets [sec].
- Net loss of -$8.6M for the period ending 2026-06-30 reflects ongoing operating losses [sec].
- Phase 2 candidate OST-HER2 faces 95 competitors in osteosarcoma, including Phase 3 programs from other sponsors [pipeline].
- Cash runway depends on timely receipt of non-dilutive VAT refunds and R&D credits, which may be subject to delays [news · 2026-04-02].
From the filings
Quoted directly from source documents.
OST-HER2 is a Listeria-based immunotherapy for osteosarcoma
“Genetically weakened and modified strain of Listeria monocytogenes that expresses HER2 peptides”
Cash runway into 2027 from financing and capital raises
“$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027”
News · May 18, 2026
Interim 3-year OS data expected early September 2026
“Interim 3-year Overall Survival data expected in early September 2026 ahead of”
News · August 17, 2026
Catalyst timeline
- 2026-09-01 · Phase 2 topline data readout for ost-her2 — Expected Phase 2 topline data readout for ost-her2 in Pulmonary Metastatic Osteosarcoma; company guidance indicates interim 3-year OS data expected early September 2026.
Risks & what to watch (3)›
Key risks
- Negative equity and net loss — Shareholders' equity of -$11.9M and net loss of -$8.6M as of 2026-06-30 indicate financial strain [sec].
- Dependence on non-dilutive refunds — Cash runway relies on timely VAT refunds and R&D tax credits from UK subsidiary, which may be delayed [news · 2026-04-02].
- Competitive landscape — OST-HER2 faces 95 competitors in osteosarcoma, including Phase 3 programs [pipeline].
What to watch
- Interim 3-year overall survival data for OST-HER2 expected early September 2026 [news · 2026-08-17].
- FDA Type C Statistical Methods Meeting in mid-September 2026 to discuss Phase 3 design and BLA pathway [news · 2026-08-17].
- Receipt of $1.9M VAT cash refund from UK subsidiary expected June 2026 [news · 2026-05-18].
- Potential UK and EU Marketing Authorisation Application for OST-HER2 [news · 2026-01-05].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run OS Therapies Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OS Therapies Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$9M
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 22, 2026- % of float
- 3.6%
- Days to cover
- 1.7
- Shares short
- 1,384,560
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OSTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for OS Therapies Inc?
OS Therapies Inc (OSTX) is a clinical-stage biopharmaceutical company focused on developing gene-edited, Listeria-based immunotherapies for osteosarcoma and other solid tumors, with lead candidate OST-HER2 in Phase 2 for metastatic osteosarcoma.
What is OS Therapies Inc's lead drug candidate?
OS Therapies Inc's most advanced tracked candidate is ost-her2 (Phase 2) for Osteosarcoma.
Who is the CEO of OS Therapies Inc?
Mr. Paul A. Romness M.P.H. is the chief executive officer of OS Therapies Inc (OSTX).
Where is OS Therapies Inc headquartered?
OS Therapies Inc (OSTX) is headquartered in Grasonville, MD, United States.
What therapeutic areas does OS Therapies Inc focus on?
OS Therapies Inc develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.